Date Issued
|
Report Number
15-03215-154
No. 1
to Veterans Health Administration (VHA)
Closure Date: 2/12/2020
The Under Secretary for Health ensures that providers establish clinical signs and symptoms consistent with androgen deficiency, prior to testing patients’ testosterone level for confirmation in alignment with Veterans Health Administration guidance.
No. 2
to Veterans Health Administration (VHA)
Closure Date: 3/4/2019
The Under Secretary for Health ensures that providers biochemically confirm hypogonadism through repeated testosterone testing prior to initiation of testosterone replacement therapy in alignment with Veterans Health Administration guidance.
No. 3
to Veterans Health Administration (VHA)
Closure Date: 3/4/2019
The Under Secretary for Health ensures that providers determine whether the etiology of hypogonadism is primary or secondary, prior to testosterone replacement therapy initiation in alignment with Veterans Health Administration guidance.
No. 4
to Veterans Health Administration (VHA)
Closure Date: 3/4/2019
The Under Secretary for Health ensures that providers discuss and document the risks and benefits of testosterone therapy with patients prior to initiation in alignment with Veterans Health Administration guidance.
No. 5
to Veterans Health Administration (VHA)
Closure Date: 3/4/2019
The Under Secretary for Health ensures that providers assess and document patients’ symptoms improvement and adverse effects within 3–6 months of initiation before continuing testosterone replacement therapy in alignment with Veterans Health Administration guidance.
No. 6
to Veterans Health Administration (VHA)
Closure Date: 3/4/2019
The Under Secretary for Health ensures that providers monitor patients’ hematocrit levels within 3–6 months of initiation, before continuing testosterone replacement therapy in alignment with Veterans Health Administration guidance.
No. 7
to Veterans Health Administration (VHA)
Closure Date: 3/4/2019
The Under Secretary for Health ensures that providers assess and document patients’ adherence to therapy and perform testosterone level test within 3–6 months of initiation, before continuing testosterone replacement therapy in alignment with Veterans Health Administration guidance.